N Belman1, E M Bonnem, H A Harvey, A Lipton. 1. Department of Medicine, M.S. Hershey Medical Center, Pennsylvania State University, Hershey 17033, USA.
Abstract
BACKGROUND: Recombinant platelet factor 4 (rPF4) is a naturally occurring protein found in platelet alpha granules that can inhibit angiogenesis. METHODS: In this Phase I trial, 9 patients with metastatic colorectal cancer who had failed 5-FU treatment received rPF4 at doses ranging from 0.3 to 3.0 mg/kg via 30-minute infusion. Three additional patients were treated with the 3 mg/kg dose over a 6-hour period of infusion. RESULTS: The only toxicity encountered was mild leg twitching in 2/3 patients treated with the 6-hour infusion. One patient with a history of phlebitis developed a lower extremity deep venous thrombosis after the first dose of rPF4. A mild rise in fibrinogen level was noted in several patients. Of the 11 evaluable patients, there were no clinical responses to treatment. CONCLUSIONS: rPF4 is well tolerated at the doses and schedules tested. No clinical responses were observed. Prolonged infusion schedules should be investigated.
BACKGROUND: Recombinant platelet factor 4 (rPF4) is a naturally occurring protein found in platelet alpha granules that can inhibit angiogenesis. METHODS: In this Phase I trial, 9 patients with metastatic colorectal cancer who had failed 5-FU treatment received rPF4 at doses ranging from 0.3 to 3.0 mg/kg via 30-minute infusion. Three additional patients were treated with the 3 mg/kg dose over a 6-hour period of infusion. RESULTS: The only toxicity encountered was mild leg twitching in 2/3 patients treated with the 6-hour infusion. One patient with a history of phlebitis developed a lower extremity deep venous thrombosis after the first dose of rPF4. A mild rise in fibrinogen level was noted in several patients. Of the 11 evaluable patients, there were no clinical responses to treatment. CONCLUSIONS:rPF4 is well tolerated at the doses and schedules tested. No clinical responses were observed. Prolonged infusion schedules should be investigated.
Authors: T E Maione; G S Gray; J Petro; A J Hunt; A L Donner; S I Bauer; H F Carson; R J Sharpe Journal: Science Date: 1990-01-05 Impact factor: 47.728
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Xiang Chen; Colin McGee; Mark Krailo; Donald A Barkauskas; John Hicks; Tsz-Kwong Man Journal: Pediatr Blood Cancer Date: 2017-05-24 Impact factor: 3.167
Authors: P Romagnani; F Annunziato; L Lasagni; E Lazzeri; C Beltrame; M Francalanci; M Uguccioni; G Galli; L Cosmi; L Maurenzig; M Baggiolini; E Maggi; S Romagnani; M Serio Journal: J Clin Invest Date: 2001-01 Impact factor: 14.808